Tag Archives: galcanezumabgnlm

FDA Approves Emgality (galcanezumab-gnlm) for the Treatment of Episodic Cluster Headache

Print this page INDIANAPOLIS, June 04, 2019 – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality (galcanezumab-gnlm) injection (300 mg) for the treatment of episodic cluster headache in adults.1 Emgality is an innovative therapeutic approach for this neurologic disease and the first and only… Read More »